New Molecule Targets Chronic Inflammation Without Harming Immune Defenses

Scientists at University College London have uncovered a natural molecule that may help control chronic inflammation. Their findings suggest a new way to treat conditions like rheumatoid arthritis without weakening the entire immune system. The discovery centres on a group of fat-derived compounds called epoxy-oxylipins, which act as a brake on harmful immune responses.

The team identified epoxydated linoleic acid, a molecule from the epoxy-oxylipin family, as a key player in reducing inflammation. It slows the formation of intermediate monocytes—immune cells that damage tissues and fuel long-term inflammation. Unlike broad-spectrum anti-inflammatory drugs, this molecule selectively limits excessive immune activity while leaving the rest of the system intact.

In a clinical test, volunteers took GSK2256294, a drug that blocks the enzyme SEH, which normally breaks down protective epoxy-oxylipins. Those who received the treatment showed much weaker inflammatory and pain responses. Researchers believe this approach could be particularly useful for rheumatoid arthritis, where immune cells attack joint cartilage. By targeting the root cause of chronic inflammation, the method may slow or even stop joint destruction.

The study opens a path for developing safer, more precise drugs that curb inflammation without suppressing the immune system entirely. If further trials confirm its effectiveness, the approach could transform treatment for rheumatoid arthritis and other chronic inflammatory diseases. The focus now shifts to refining therapies based on these natural immune-regulating molecules.